Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Sep;22(9):1151-7.
doi: 10.1007/s00192-011-1444-x. Epub 2011 May 13.

Weight loss improves fecal incontinence severity in overweight and obese women with urinary incontinence

Alayne D Markland  1 , Holly E Richter, Kathryn L Burgio, Deborah L Myers, Alexandra L Hernandez, Leslee L Subak
Affiliations
Randomized Controlled Trial

Weight loss improves fecal incontinence severity in overweight and obese women with urinary incontinence

Alayne D Markland et al. Int Urogynecol J. 2011 Sep.

Abstract

Introduction/hypothesis: To estimate the effect of weight loss on fecal incontinence (FI) severity among overweight and obese women with urinary incontinence, we analyzed data from women randomized to a weight loss intervention or control condition.

Methods: The modified Fecal Incontinence Severity Index (FISI) was administered at 6, 12, and 18 months in 338 women. Repeated measures analyses identified factors associated with improved FISI scores among women with baseline scores >0.

Results: FISI scores improved in 45 (13%) across all time points among the 291 women (87%) completing the trial. Improved scores were associated with a one-point lower urinary tract symptoms (LUTS) score, p < 0.01. Improved liquid stool FI frequency was associated with ≥ 5 kg weight loss (p = 0.001), 10-g increase in fiber intake (p = 0.05), and decreased LUTS (p = 0.003).

Conclusions: FI severity improved with weight loss. Women with liquid stool FI losing at least 5 kg and/or increased dietary fiber intake had improved FI frequency.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Markland AD (Pfizer consultant), Myers DL, Hernandez AL, Burgio KL (Pfizer, Astellas, Johnson & Johnson, consultant) have no potential conflicts of interest to disclose. Richter HE, a Pfizer investigator, was initiated a grant funding (Xanodyne consultant). Subak LL received Pfizer grant/research support.

References

    1. Nelson R, Norton N, Cautley E, Furner S. Community-based prevalence of anal incontinence. JAMA. 1995;274:559–561. - PubMed
    1. We W, Borrud L, Goode PS, et al. Fecal incontinence in US adults: epidemiology and risk factors. Gastroenterol. 2009;137:512–517. - PMC - PubMed
    1. Nygaard I, Barber MD, Burgio KL, et al. Prevalence of symptomatic pelvic floor disorders in US women. JAMA. 2008;300:1311–1316. - PMC - PubMed
    1. Lawrence JM, Lukacz ES, Nager CW, Hsu J-WY, Luber KM. Prevalence and co-occurrence of pelvic floor disorders in community-dwelling women. Obstet Gynecol. 2008;111:678–685. - PubMed
    1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006;295:1549–1555. - PubMed

Publication types